We are live on ! Find out more
CCM

Camber Capital Management Portfolio holdings

AUM $1.07B
1-Year Est. Return 8.19%
This Fund
S&P 500
This Quarter Est. Return
+5.46%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$2.81B
AUM Growth
-$1.51B
Cap. Flow
-$1.47B
Cap. Flow %
-52.15%
Top 10 Hldgs %
78.26%
Holding
40
New
1
Increased
8
Reduced
18
Closed
8

Top Buys

Rank Stock Value
1
ZBH icon
Zimmer Biomet
ZBH
+$69M
2
BAX icon
Baxter International
BAX
+$36.8M
3
HUM icon
Humana
HUM
+$20.3M
4
CI icon
Cigna
CI
+$15.1M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$3.36M

Top Sells

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$220M
2
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$142M
3
GSK icon
GSK
GSK
+$91.5M
4
PTCT icon
PTC Therapeutics
PTCT
+$84.8M
5
VTRS icon
Viatris
VTRS
+$78.7M

Sector Composition

Rank Sector Weight
1 Healthcare 56.93%
2 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$771B
$839M 29.81%
1,500,000
-1,000,000
-40% -$588M
ZBH icon
2
Zimmer Biomet
ZBH
$18.8B
$255M 9.05%
2,250,000
+645,000
+40% +$69M
BAX icon
3
Baxter International
BAX
$12.8B
$197M 6.99%
5,750,000
+1,125,000
+24% +$36.8M
HUM icon
4
Humana
HUM
$43.9B
$192M 6.81%
725,000
+75,000
+12% +$20.3M
PFE icon
5
CALL
Pfizer
PFE
$143B
$172M 6.12%
6,800,000
+1,800,000
+36% +$47.1M
XBI icon
6
PUT
State Street SPDR S&P Biotech ETF
XBI
$10B
$162M 5.76%
+2,000,000
New +$179M
CVS icon
7
CVS Health
CVS
$135B
$152M 5.42%
2,250,000
-750,000
-25% -$44.9M
GMED icon
8
Globus Medical
GMED
$11.1B
$91.5M 3.25%
1,250,000
+25,000
+2% +$2.07M
PTCT icon
9
PTC Therapeutics
PTCT
$6.18B
$76.4M 2.72%
1,500,000
-1,700,000
-53% -$84.8M
CI icon
10
Cigna
CI
$78.4B
$65.8M 2.34%
200,000
+50,000
+33% +$15.1M
VTRS icon
11
Viatris
VTRS
$20.8B
$65.3M 2.32%
7,500,000
-7,500,000
-50% -$78.7M
PFE icon
12
Pfizer
PFE
$143B
$63.4M 2.25%
2,500,000
-2,500,000
-50% -$65.4M
QGEN icon
13
Qiagen
QGEN
$8.62B
$56.2M 2%
1,400,000
-58,333
-4% -$2.45M
ASND icon
14
Ascendis Pharma A/S
ASND
$16.5B
$54.6M 1.94%
350,000
-450,000
-56% -$64.3M
SRPT icon
15
Sarepta Therapeutics
SRPT
$1.64B
$51.1M 1.81%
800,000
-200,000
-20% -$21.1M
BKD icon
16
Brookdale Senior Living
BKD
$3.55B
$39.1M 1.39%
6,250,000
-7,685,000
-55% -$41.1M
GSK icon
17
CALL
GSK
GSK
$107B
$38.7M 1.38%
1,000,000
-4,000,000
-80% -$146M
BMRN icon
18
BioMarin Pharmaceuticals
BMRN
$11.9B
$35.3M 1.26%
500,000
+50,000
+11% +$3.36M
CON
19
Concentra Group Holdings
CON
$4.04B
$34.7M 1.23%
1,600,000
-1,900,000
-54% -$41.8M
EVH icon
20
Evolent Health
EVH
$371M
$28.4M 1.01%
3,000,000
-1,000,000
-25% -$10.1M
IONS icon
21
Ionis Pharmaceuticals
IONS
$8.93B
$21.9M 0.78%
725,000
+100,000
+16% +$3.27M
MYGN icon
22
Myriad Genetics
MYGN
$476M
$20.8M 0.74%
2,350,000
-750,000
-24% -$9.01M
ZIMV
23
DELISTED
ZimVie
ZIMV
$20.4M 0.72%
1,885,000
-840,000
-31% -$11M
MLTX icon
24
MoonLake Immunotherapeutics
MLTX
$1.56B
$17.2M 0.61%
441,000
– –
DNLI icon
25
Denali Therapeutics
DNLI
$3.79B
$17M 0.6%
1,250,000
-1,000,000
-44% -$19.2M
1
2

Similar funds

PP
PrairieView Partners St. Paul, Minnesota $1.03B AUM 11.4% 1-Year Est. Return
SAF
Smith Anglin Financial Dallas, Texas $1.1B AUM 14.08% 1-Year Est. Return
NRD
Nebula Research & Development New York $1.17B AUM 15.19% 1-Year Est. Return
FC
Forte Capital Rochester, New York $930M AUM 24.11% 1-Year Est. Return
GIM
Grassi Investment Management Santa Clara, California $1.26B AUM 23.4% 1-Year Est. Return
SC
Savoie Capital Chicago, Illinois $805M AUM 19.48% 1-Year Est. Return
BWA
Bordeaux Wealth Advisors Menlo Park, California $781M AUM 26.55% 1-Year Est. Return
CCP
Camelot Capital Partners Laguna Beach, California $686M AUM 163.55% 1-Year Est. Return

Camber Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, Camber Capital Management held 40 positions worth $2.81B, down 35% from $4.32B the previous quarter. Its ten largest holdings account for 78% of the portfolio.

Camber Capital Management withdrew a net $1.47B in Q1 2025, closing 8 positions and reducing 18 holdings. Its most notable exit was Medtronic, an estimated $220M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 57% of assets, down from 58% a quarter earlier, followed by Consumer Staples.

Against the trend, Camber Capital Management added an estimated $69M to Zimmer Biomet.

  • Camber Capital Management added most to Zimmer Biomet in Q1 2025, an estimated $69M increase.
  • Camber Capital Management's biggest Q1 2025 reduction was PTC Therapeutics, cutting an estimated $84.8M.
  • Camber Capital Management fully exited Medtronic in Q1 2025, selling an estimated $220M.
  • Camber Capital Management's ten largest holdings make up 78% of its $2.81B portfolio in Q1 2025.
  • Camber Capital Management opened 1 new position and closed 8 in Q1 2025.
  • Camber Capital Management's portfolio value fell 35% quarter-over-quarter to $2.81B.

Based on Camber Capital Management's 13F filing for Q1 2025, filed 15 May 2025.